Ascendis Pharma AS annual operating income for fiscal TTM was €266 million, compared with -€131 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Operating Income (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (EBIT) | €266M | (€131M) | (€279M) | (€456M) | (€562M) | (€452M) | (€331M) | (€227M) | (€155M) | (€112M) | (€73M) | (€42M) | (€12M) | €5M | €2M |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Operating Income (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Income (EBIT) | €220M | €25M | €10M | €11M | (€53M) | (€104M) | €0M | (€97M) | (€133M) |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More ASND metrics: Revenue · Gross Profit · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All ASND financial statements → Interactive ASND charts →
About TickerBase · Data methodology & sources · Privacy · Terms